Long-term safety study of atumelnant for adrenal hyperplasia
Treatments studied
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a previous Crinetics study of atumelnant for congenital adrenal hyperplasia.
- Women who could get pregnant must agree to use highly effective birth control during the study and for 2 weeks after the last dose.
- If you are a man, you must use a condom with a partner who could become pregnant, or be abstinent, during the study and for 2 weeks after the last dose.
- You cannot have serious medical conditions like heart disease, severe kidney or liver problems, uncontrolled diabetes, or a history of alcohol or drug abuse in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This study looks at the long-term experiences of adults with classic congenital adrenal hyperplasia (CAH), a condition affecting hormone production. It aims to understand patient satisfaction and health outcomes over time.
This study helps young people with congenital adrenal hyperplasia (a condition affecting hormone production) move smoothly from pediatric to adult care. Researchers will develop and test a transition program with patients, caregivers, and healthcare providers to make this shift easier and safer.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.